Effect of Arthrospira Platensis (Spirulina) as an Adjunct to Scaling and Root Planing on Salivary Antioxidant Levels in Chronic Periodontitis Subjects

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02886676

Enrollment

Registered

2016-09-01

Start date

2015-05-31

Completion date

2016-05-31

Last updated

2016-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

Introduction- Oxidative stress plays a causative role in pathogenesis of periodontal disease. It has been reported that Spirulina platensis or its active ingredient C phycocyanin (CPC) exerts anti-inflammatory, anti-oxidative and inhibitory effects on prostaglandin and leukotriene biosynthesis. Aim- To evaluate the effect of dietary spirulina as an adjunct to SRP on salivary antioxidants level in CP subjects. Materials And Methods- The study was a randomized double-blind clinical and biochemical trial in which 70 subjects with CP in the age group of 40-55 years, reporting to Department of Periodontology, TKDC and RC, New Pargaon, were equally and randomly divided into Test Group (TG) and Control Group (CG). TG was given 2 gm Spirulina capsules daily, after meals for 1 month and CG was not given any supplementary diet. SRP was done at baseline in TG and CG. Whole saliva sample was collected. Clinical and biochemical parameters will be recorded at baseline, 1 month & 3 months.

Interventions

DRUGSpirulina capsules

Spirulina capsules 2gm daily for 1 month

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Subjects with CP (moderate and severe)as per CDC criteria 2007. 2. Patients without any known systemic diseases.

Exclusion criteria

1. Patients who have taken anti-inflammatory/antibiotic/antioxidant within 3 months of beginning of study. 2. Subjects who have undergone periodontal treatment within six months of inception of study. 3. Tobacco habits in any form and alcoholics. 4. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Superoxide dismutase (SOD)	3 month
Malondialdehyde (MDA)	3 month

Secondary

Measure	Time frame
Sulcus bleeding index (SBI)	3 month
Gingival bleeding index	3 month
Clinical Attachment Level (CAL)	3 month
Probing depth (PD)	3 month
plaque index	3 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026